^
    6d
    SYSKY-2023-1262-02: Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=32, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Trial completion date: Sep 2026 --> Sep 2028 | Trial primary completion date: Mar 2026 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    AiTan (rivoceranib) • Teysuno (gimeracil/oteracil/tegafur) • AiRuiLi (adebrelimab)
    7d
    Apatinib inhibits synovial sarcoma progression and angiogenesis via VEGFR2-mediated AKT/FOXO3A and ERK1/2/FOXM1 signaling pathways. (PubMed, Cell Death Discov)
    In vivo, apatinib markedly suppressed xenograft tumor growth and modulated the corresponding signaling pathways. Collectively, our findings identify apatinib as a promising therapeutic agent that disrupts interconnected survival and angiogenic networks in SS.
    Journal
    |
    KDR (Kinase insert domain receptor) • FOXM1 (Forkhead Box M1) • FOXO3 (Forkhead box O3) • NOS3 (Nitric oxide synthase 3)
    |
    AiTan (rivoceranib)
    9d
    A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors (clinicaltrials.gov)
    P=N/A, N=208, Not yet recruiting, Henan Cancer Hospital
    New trial
    |
    AFP (Alpha-fetoprotein)
    |
    5-fluorouracil • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • oxaliplatin • leucovorin calcium
    12d
    Metachronous hepatocellular carcinoma after partial response of advanced intrahepatic cholangiocarcinoma treated with radiotherapy combined with apatinib and camrelizumab: a case report. (PubMed, Front Oncol)
    Radiotherapy combined with anti-angiogenic and immunotherapy is an effective option for advanced unresectable iCCA. It also emphasizes that active pathological biopsy is essential for new hepatic lesions after iCCA remission to clarify diagnosis and avoid misdiagnosis-induced inappropriate treatment.
    Journal
    |
    AFP (Alpha-fetoprotein)
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    12d
    Apatinib enhances anti-PD-1 efficacy by inhibiting Exo70-mediated exosome secretion in pMMR/MSS colorectal cancer. (PubMed, NPJ Precis Oncol)
    This inhibitory effect was mediated through the regulation of Exo70. Collectively, our findings indicate that apatinib enhances the efficacy of camrelizumab in pMMR/MSS colorectal cancer and provide a theoretical rationale for the combined use of camrelizumab and apatinib in this patient population.
    Journal • pMMR
    |
    PD-L1 (Programmed death ligand 1)
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    13d
    FASCINATE-N: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (clinicaltrials.gov)
    P2, N=716, Recruiting, Fudan University | Trial completion date: Sep 2028 --> Sep 2029 | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8) • FOXC1 (Forkhead Box C1)
    |
    Herceptin (trastuzumab) • carboplatin • Focus V (anlotinib) • Perjeta (pertuzumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Irene (pyrotinib) • albumin-bound paclitaxel • cyclophosphamide • letrozole • epirubicin • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • Andewei (benmelstobart) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020) • Idafang (ivonescimab) • bulumtatug fuvedotin (9MW2821) • AiRuiLi (adebrelimab) • IBI-354 • SHR-4602 • TQB2102 • TQB2868 • anbenitamab repodatecan (JSKN003) • tizetatug rezetecan (SHR-A1921)
    13d
    RA-A-NP: Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction Cancer (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Henan Cancer Hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    AiTan (rivoceranib) • albumin-bound paclitaxel • retlirafusp alfa (SHR-1701)
    14d
    CLARITY-Gastric 01: AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (clinicaltrials.gov)
    P3, N=592, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression • CLDN18.2 positive • CLDN1 positive
    |
    paclitaxel • docetaxel • AiTan (rivoceranib) • Cyramza (ramucirumab) • irinotecan • Lonsurf (trifluridine/tipiracil) • sonesitatug vedotin (AZD0901)
    19d
    MA-HCC-II-015: A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=21, Completed, Shandong Cancer Hospital and Institute | Active, not recruiting --> Completed
    Trial completion
    |
    5-fluorouracil • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • oxaliplatin • leucovorin calcium
    24d
    Efficacy and Safety of Camrelizumab Plus Apatinib in Patients With Refractory Chordoma: A Phase II Clinical Trial. (PubMed, J Clin Oncol)
    Combination of camrelizumab and apatinib offered encouraging efficacy with manageable toxicity in chordoma treatment. CDKN2A alterations are associated with worse prognosis and may prove to be a potential biomarker for treatment selection.
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    CDKN2A deletion
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    26d
    A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC (clinicaltrials.gov)
    P2/3, N=66, Recruiting, Guangzhou Virotech Pharmaceutical Co., Ltd.
    New P2/3 trial • Checkpoint inhibition
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    27d
    HAIC-TACE Plus Apatinib and Camrelizumab for Liver Cancer (clinicaltrials.gov)
    P1/2, N=315, Not yet recruiting, Shanghai Zhongshan Hospital
    New P1/2 trial
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)